Product Information
ETHOSUXIMIDE 250 MG/5 ML SOLN is a generic product labeled by PAI Holdings LLC, priced at $0.0939 per ML under NDC 00121067016. Its NADAC has been published 619 times since Aug 27, 2014.
FDA first approved this application on Nov 22, 2000. Its Orange Book therapeutic-equivalence code is AA.
The Low Outlier badge above means this manufacturer's average price in the ETHOSUXIMIDE market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/5mL
Manufacturer
PAI Holdings LLCNDC
00121067016
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ETHOSUXIMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA040253FDA Approved
11/22/2000
TE Code
AA
On Market Since
11/22/2000
Pharmacological Classes
Price Statistics
The NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has been published 619 times since Aug 27, 2014, and over the history we have for it it has declined 59.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0939 per ML |
|---|---|
| All-time high | $0.3226 (Feb 11, 2015) |
| All-time low | $0.0626 (Jul 20, 2022) |
| 52-week high | $0.0965 |
| 52-week low | $0.0879 |
| Median price | $0.1933 |
| Average price | $0.1802 |
| Largest weekly change | +46.5% (Aug 22, 2018) |
| Weeks tracked | 619 |
| Tracking since | Aug 27, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ETHOSUXIMIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ETHOSUXIMIDE 250 MG/5 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for ETHOSUXIMIDE 250 MG/5 ML SOLN, manufactured by PAI Holdings LLC, is $0.0939 per ML (NDC 00121067016), effective Aug 19, 2026.
How has the price of ETHOSUXIMIDE 250 MG/5 ML SOLN changed over time?
Over the history we have for it, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has declined 59.2%. It has been tracked across 619 weekly CMS publications since Aug 27, 2014.
What are the highest and lowest recorded NADAC prices for ETHOSUXIMIDE 250 MG/5 ML SOLN?
Since Aug 27, 2014, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has ranged from a low of $0.0626 (Jul 20, 2022) to a high of $0.3226 (Feb 11, 2015), with a median of $0.1933 per ML.
Are there cheaper alternatives to ETHOSUXIMIDE 250 MG/5 ML SOLN?
No other NADAC-published product currently shares the active ingredient and strength of ETHOSUXIMIDE 250 MG/5 ML SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ETHOSUXIMIDE 250 MG/5 ML SOLN?
ETHOSUXIMIDE 250 MG/5 ML SOLN (NDC 00121067016) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.